SKIV2L2 Antibody

What is SKIV2L2 and what cellular functions does it perform?

SKIV2L2 (Superkiller viralicidic activity 2-like 2), also known as MTREX or MTR4, is a 118 kDa ATP-dependent RNA helicase primarily located in the nucleus. It plays critical roles in:

• RNA surveillance via the nuclear exosome

• Processing and degradation of specific noncoding RNAs

• Pre-mRNA splicing as part of the spliceosome C complex

• Regulation of replication-dependent histone mRNA turnover

• Cell differentiation and mitotic progression

• Telomeric DNA-RNA hybrid stability in G2 phase

The protein contains one helicase ATP-binding domain and one helicase C-terminal domain that facilitate RNA unwinding during RNA processing. SKIV2L2 is widely expressed across various tissues and highly conserved across species including humans, mice, rats, and even zebrafish .

How do SKIV2L2 antibodies differ in their target epitopes and applications?

SKIV2L2 antibodies target different epitopes across the protein structure, affecting their utility in specific applications:

The choice of epitope is particularly important when investigating specific SKIV2L2 functions. For example, antibodies targeting the helicase domain can be critical for studies on RNA processing mechanisms, while those targeting regions involved in protein-protein interactions might be better for co-immunoprecipitation experiments .

What are the optimal conditions for detecting SKIV2L2 by Western blot?

For optimal Western blot detection of SKIV2L2:

• Sample preparation:

  • Use nuclear extracts or whole cell lysates from tissues with known SKIV2L2 expression (brain, thymus, testis are recommended)

  • Include protease inhibitors to prevent degradation

• Electrophoresis conditions:

  • Use 6-8% SDS-PAGE gels due to the large size of SKIV2L2 (118 kDa)

  • Run at lower voltage (80-100V) for better resolution of high molecular weight proteins

• Transfer parameters:

  • Wet transfer at 30V overnight at 4°C for efficient transfer of large proteins

  • Use PVDF membrane rather than nitrocellulose for better protein retention

• Antibody dilutions and incubation:

  • Primary antibody: 1:500-1:2000 dilution (optimize based on specific antibody)

  • Incubate overnight at 4°C for maximum sensitivity

  • Secondary antibody: 1:5000-1:10000, incubate 1-2 hours at room temperature

• Detection:

  • Enhanced chemiluminescence (ECL) with extended exposure times (1-5 minutes) may be necessary

How can I optimize immunoprecipitation protocols for SKIV2L2?

Optimizing SKIV2L2 immunoprecipitation requires careful consideration of several factors:

• Lysis buffer composition:

  • Use buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, with protease inhibitors

  • For nuclear proteins like SKIV2L2, include 0.1% SDS to aid in nuclear membrane disruption

• Antibody selection and amount:

  • Use 2-4 μg of antibody per 400-1000 μg of total protein lysate

  • Antibodies validated specifically for IP applications yield better results

• Pre-clearing step:

  • Pre-clear lysate with protein A/G beads for 1 hour at 4°C to reduce non-specific binding

• Incubation conditions:

  • Overnight incubation at 4°C with gentle rotation improves binding

  • Wash 4-5 times with lysis buffer containing reduced detergent concentration

• RNA-protein interaction studies:

  • For RNA immunoprecipitation (RIP), include RNase inhibitors in all buffers

  • UV crosslinking (254 nm for 2-3 minutes) before lysis can preserve RNA-protein interactions

Cross-linked immunoprecipitation (CLIP) has been successfully used to demonstrate SKIV2L2 binding to histone mRNAs, providing evidence for its direct role in histone mRNA turnover .

Why might SKIV2L2 detection vary between different cell types or experimental conditions?

Variations in SKIV2L2 detection can stem from multiple factors:

• Cell cycle-dependent expression:

  • SKIV2L2 shows increased association with telomeres specifically in G2 phase cells

  • Synchronize cells (using thymidine block or nocodazole) to standardize detection

• Subcellular localization changes:

  • Primarily nuclear, but localization patterns can vary with cellular state

  • Cellular fractionation may be necessary for consistent detection

• Expression level differences:

  • Higher expression in proliferating cells compared to differentiated cells

  • Cell type-specific expression patterns (higher in testis, thymus, and brain)

• Technical factors:

  • Antibody accessibility issues due to protein-protein interactions or chromatin association

  • Fixation methods for immunofluorescence can affect epitope availability

• Post-translational modifications:

  • Modifications may mask epitopes or alter antibody binding efficiency

  • Consider using phosphatase treatment to eliminate interference from phosphorylation

To address these variables, always include appropriate controls and standardize experimental conditions when comparing SKIV2L2 across different samples or conditions.

How can I confirm the specificity of my SKIV2L2 antibody?

Confirming antibody specificity is crucial for reliable SKIV2L2 research:

• RNAi knockdown validation:

  • Transfect cells with siRNA targeting SKIV2L2 (siRNA ID #177475 has been validated)

  • Western blotting should show reduced signal (typically 6-7 fold reduction)

  • Include non-targeting control siRNA

• Overexpression controls:

  • Express tagged SKIV2L2 (such as FLAG or GFP-tagged) and confirm detection with both tag antibody and SKIV2L2 antibody

• Multiple antibody comparison:

  • Use antibodies targeting different epitopes of SKIV2L2

  • Consistent detection patterns increase confidence in specificity

• Immunoprecipitation followed by mass spectrometry:

  • Confirm the identity of the immunoprecipitated protein

  • Should detect SKIV2L2 peptides with high confidence

• Knockout verification:

  • If available, use SKIV2L2 knockout cell lines or tissues as negative controls

  • Complete absence of signal confirms specificity

How can SKIV2L2 antibodies be used to investigate RNA surveillance mechanisms?

SKIV2L2 antibodies can be leveraged to explore RNA surveillance through several sophisticated approaches:

• RNA Immunoprecipitation (RIP):

  • Use SKIV2L2 antibodies to immunoprecipitate protein-RNA complexes

  • Analyze bound RNAs by RT-qPCR or RNA-seq to identify SKIV2L2 RNA targets

  • Research has identified replication-dependent histone mRNAs (H1, H2A, H2B, H3, H4) as SKIV2L2 targets

• Cross-linking Immunoprecipitation (CLIP):

  • UV crosslinking followed by SKIV2L2 immunoprecipitation preserves direct RNA-protein interactions

  • High-throughput sequencing of immunoprecipitated RNAs can map the SKIV2L2-bound transcriptome

• Proximity Ligation Assay (PLA):

  • Combine SKIV2L2 antibodies with antibodies against other RNA surveillance factors

  • PLA can detect protein-protein interactions in situ, as demonstrated for SKIV2L2-TRF2 interaction at telomeres

• ChIP-sequencing adaptations:

  • ChIP-dot blot has confirmed SKIV2L2 recruitment to telomeres specifically in G2 phase cells

  • Can be adapted to identify genomic loci where SKIV2L2 associates with nascent transcripts

• Immunofluorescence combined with RNA FISH:

  • Visualize co-localization of SKIV2L2 with specific RNA species

  • Has been used to show SKIV2L2 localization at telomeres

These approaches have revealed SKIV2L2's role in replication-dependent histone mRNA turnover, illustrating how its depletion leads to histone mRNA accumulation and G2/M phase arrest .

What role does SKIV2L2 play in cell cycle progression and how can this be studied using antibodies?

SKIV2L2's involvement in cell cycle progression, particularly in G2/M phase, can be investigated using antibody-based techniques:

• Cell cycle synchronization combined with immunoblotting:

  • Synchronize cells at different cell cycle phases (using thymidine block, nocodazole, etc.)

  • Analyze SKIV2L2 expression levels and modifications across the cell cycle

  • Research has shown that SKIV2L2 depletion results in G2/M phase arrest

• Co-immunoprecipitation with cell cycle regulators:

  • Immunoprecipitate SKIV2L2 and probe for interactions with cell cycle proteins

  • Can reveal potential regulatory mechanisms and pathways

• Immunofluorescence microscopy with cell cycle markers:

  • Co-stain for SKIV2L2 and cell cycle phase-specific markers

  • Analyze changes in localization patterns throughout the cell cycle

• Chromatin immunoprecipitation (ChIP):

  • Investigate SKIV2L2 association with specific chromatin regions during different cell cycle phases

  • Has shown enriched SKIV2L2 presence at telomeres in G2 phase

• FACS analysis after SKIV2L2 knockdown/overexpression:

  • Fixed cells stained with propidium iodide can be analyzed for cell cycle distribution

  • SKIV2L2 knockdown has been shown to increase the proportion of cells in G2/M phase by 23%

Research has established that SKIV2L2 depletion impairs cellular proliferation by approximately 30% and causes accumulation of cells in G2/M phase, likely due to its role in histone mRNA turnover. This differs from the G1 arrest typically seen during cell differentiation, suggesting a specific mechanism linking RNA surveillance to mitotic progression .

How should I select between polyclonal and monoclonal SKIV2L2 antibodies for specific applications?

The choice between polyclonal and monoclonal SKIV2L2 antibodies depends on the specific research requirements:

Application-specific recommendations:

• For Western blot: Both types work well; polyclonals often give stronger signals

• For immunoprecipitation: Monoclonals may offer cleaner results with less non-specific binding

• For ChIP experiments: Monoclonals typically provide more consistent results

• For detecting post-translationally modified SKIV2L2: Epitope-specific monoclonals may be required

Consider using both types in complementary experiments to validate findings.

What are the key technical considerations when performing immunofluorescence with SKIV2L2 antibodies?

Successful immunofluorescence detection of SKIV2L2 requires attention to several technical details:

• Fixation method optimization:

  • 4% paraformaldehyde (10-15 minutes) preserves structural integrity

  • For detecting nuclear SKIV2L2, methanol fixation (10 minutes at -20°C) may improve nuclear epitope accessibility

• Permeabilization protocol:

  • 0.25-0.5% Triton X-100 for 10 minutes ensures nuclear penetration

  • Avoid overly harsh permeabilization which can damage nuclear architecture

• Blocking conditions:

  • 5% BSA or 5-10% normal serum (from secondary antibody species) for 1 hour

  • Include 0.1% Triton X-100 in blocking buffer to maintain permeabilization

• Antibody dilution and incubation:

  • Primary antibody: 1:50-1:500 dilution (optimize for each antibody)

  • Incubate overnight at 4°C for maximum sensitivity and specificity

  • Secondary antibody: 1:200-1:1000, incubate 1-2 hours at room temperature

• Nuclear counterstaining:

  • DAPI (1:1000) for 5-10 minutes provides nuclear reference

  • Consider co-staining with nuclear membrane markers for precise localization

• Signal amplification:

  • When detecting low abundance SKIV2L2, tyramide signal amplification can improve sensitivity

  • Alexa Fluor-conjugated secondary antibodies offer improved signal-to-noise ratio

• Confocal microscopy settings:

  • Use sequential scanning to avoid bleed-through when co-staining

  • Z-stack imaging improves detection of nuclear proteins

SKIV2L2 typically shows nuclear localization with possible enrichment at specific subnuclear structures, particularly in G2 phase cells where it associates with telomeres .

SKIV2L2 Antibody Research Questions in Cell Biology Applications

How does SKIV2L2 mediate differential regulation of RNA targets during cell cycle phases?

SKIV2L2 (MTR4) exhibits cell cycle-dependent regulation of RNA targets, with distinct mechanisms operating in different phases:

During G2 phase, SKIV2L2 demonstrates enhanced recruitment to telomeres, where it regulates telomeric DNA-RNA hybrids and prevents telomere replication stress . This function appears independent of its helicase domain, suggesting a structural rather than enzymatic role in this context.

For histone mRNA regulation, SKIV2L2 functions as an active RNA helicase, directly binding histone transcripts and facilitating their turnover. This process is critical during S/G2 transition and affects G2/M progression .

Methodological approaches to study phase-specific functions include:

• Cell synchronization using double thymidine block (for S-phase) or RO-3306 (for G2-phase)

• ChIP-seq or DRIP-seq (DNA-RNA immunoprecipitation) to map SKIV2L2 chromatin associations

• RNA half-life measurements using actinomycin D treatment followed by qRT-PCR

• Proximity ligation assays to detect phase-specific protein interactions

Research has shown that SKIV2L2 depletion doubles histone H4 mRNA half-life from 34 to 72 minutes, demonstrating its direct role in RNA turnover kinetics. Additionally, its association with telomeres specifically in G2 phase suggests orchestrated recruitment mechanisms that warrant further investigation .

How can cross-reactivity issues with SKIV2L2 antibodies be identified and mitigated?

Cross-reactivity represents a significant challenge in SKIV2L2 antibody applications due to protein homology with related helicases and variable specificity across species:

Identification strategies:

• Validation in knockout/knockdown systems:

  • Compare antibody signal in control vs. SKIV2L2-depleted samples using siRNA knockdown

  • RNAi using siRNA ID #177475 has been validated to reduce SKIV2L2 levels 6-7 fold

• Multiple antibody comparison:

  • Test antibodies targeting different epitopes (N-terminal, central, C-terminal)

  • Concordant signals increase confidence in specificity

• Mass spectrometry verification:

  • Analyze immunoprecipitated proteins to confirm SKIV2L2 and identify potential cross-reactive proteins

  • Check for presence of related helicases like SKIV2L, DDX1, or other DEAD/DEAH box proteins

Mitigation approaches:

• Pre-adsorption protocols:

  • Pre-incubate antibody with recombinant related proteins to reduce cross-reactivity

  • Test antibody dilution series to optimize signal-to-noise ratio

• Epitope-specific considerations:

  • N-terminal antibodies (amino acids 1-304) typically show less cross-reactivity with related helicases

  • Avoid antibodies targeting highly conserved helicase domains when specificity is critical

• Species-specific validation:

  • Verify reactivity in human, mouse, and rat samples separately

  • Consider species-specific antibodies for cross-species studies

When absolute specificity is required, using tagged SKIV2L2 constructs (FLAG, HA, or GFP) and corresponding tag antibodies can circumvent cross-reactivity issues entirely.

What are the best approaches to study SKIV2L2 interactions with the nuclear exosome complex?

Investigating SKIV2L2's interactions with the nuclear exosome requires specialized techniques that preserve native complex integrity:

• Optimized co-immunoprecipitation protocols:

  • Use low-stringency buffers (150mM NaCl, 0.1-0.5% NP-40) to maintain complex integrity

  • Include RNase treatment controls to distinguish RNA-dependent from direct protein interactions

  • Sequential IP (first SKIV2L2, then exosome components) can confirm complex composition

• Proximity-based interaction studies:

  • BioID or TurboID fusion proteins to identify proteins in close proximity to SKIV2L2

  • Proximity ligation assay (PLA) to visualize and quantify interactions with specific exosome components

  • FRET or BRET approaches for real-time interaction dynamics

• Fractionation-based analyses:

  • Glycerol gradient fractionation to separate intact complexes

  • Size exclusion chromatography combined with western blotting

  • Blue native PAGE to preserve native complexes for western analysis

• Functional interaction assays:

  • RNA decay assays comparing SKIV2L2 depletion with exosome component depletion

  • Rescue experiments with wild-type vs. interaction-deficient SKIV2L2 mutants

When performing these analyses, it's crucial to account for the dynamic nature of SKIV2L2-exosome interactions, which may differ based on cell cycle phase, RNA substrate availability, and cellular stress conditions. Studies have shown that SKIV2L2 directly aids in the turnover of replication-dependent histone mRNAs through its interaction with the exosome complex, with knockdown resulting in significant accumulation of these transcripts .

How is SKIV2L2 function altered in cancer and what methodologies can assess these changes?

SKIV2L2's role in cancer involves multiple aspects of RNA metabolism and cell cycle regulation that can be assessed through specialized techniques:

• Expression and localization alterations:

  • Compare SKIV2L2 levels between matched tumor/normal tissues using immunohistochemistry

  • Assess subcellular localization changes using co-localization with nuclear/nucleolar markers

  • Research in N2A and P19 cancer cell lines shows SKIV2L2 depletion reduces proliferation by 30%

• Functional impact assessment:

  • Measure RNA surveillance efficiency using reporter constructs containing premature termination codons

  • Analyze histone mRNA levels and half-life in cancer cells with high vs. low SKIV2L2 expression

  • Examine telomere integrity using immunofluorescence-FISH with SKIV2L2 and telomere probes

• Cell cycle and proliferation analysis:

  • Flow cytometry with propidium iodide staining reveals SKIV2L2 depletion causes G2/M arrest

  • MTT proliferation assays show SKIV2L2 knockdown reduces cancer cell proliferation by 22-38%

  • Combined with differentiation markers to assess impact on cancer cell stemness

• High-throughput approaches:

  • RNA-seq analysis comparing SKIV2L2 targets in normal vs. cancer cells

  • CLIP-seq to identify cancer-specific RNA interactions

  • Proteomics to map altered SKIV2L2 interaction networks in malignant cells

Recent research demonstrates that SKIV2L2 depletion leads to 23% increase in G2/M phase cells, suggesting its importance in maintaining cancer cell proliferation. Additionally, the finding that SKIV2L2 knockdown enhances cell differentiation in cancer cell lines indicates potential therapeutic relevance .

What experimental design best evaluates the impact of SKIV2L2 mutations on RNA processing pathways?

Evaluating SKIV2L2 mutation effects requires a comprehensive experimental approach spanning molecular, cellular, and functional analyses:

• Mutation characterization and modeling:

  • Structure-based analysis of mutations (particularly within helicase domains)

  • Comparison with evolutionary conservation patterns across species

  • In silico prediction of functional impacts using protein modeling

• Biochemical activity assessment:

  • Recombinant protein purification of wild-type and mutant SKIV2L2

  • In vitro helicase activity assays using radiolabeled RNA substrates

  • ATP hydrolysis assays to measure enzymatic efficiency

• Cellular complementation studies:

  • CRISPR/Cas9 knockout of endogenous SKIV2L2 followed by rescue with wild-type or mutant constructs

  • Inducible expression systems for temporal control of mutant protein expression

  • Quantification of RNA target accumulation using RT-qPCR for histone mRNAs and other SKIV2L2 substrates

• RNA processing pathway analysis:

  • Global RNA sequencing to identify differentially processed transcripts

  • 3' RACE to detect changes in RNA 3' end processing

  • Pulse-chase labeling of RNAs to measure processing kinetics and decay rates

• Interaction network assessment:

  • Co-immunoprecipitation comparing wild-type and mutant SKIV2L2 binding to exosome components

  • Proximity ligation assays to quantify changes in protein-protein interactions

  • ChIP-seq to map altered chromatin association patterns

When analyzing results, special attention should be paid to histone mRNA metabolism, as SKIV2L2 has been shown to directly bind these transcripts and regulate their turnover. Mutations affecting this function have significant downstream effects on cell cycle progression, particularly at the G2/M phase transition .